• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Exits

Triton’s Pharmanovia tipped as 2023 sale candidate

  • Rachel Lewis and Christel Thunell
  • 02 November 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Corporate advisors expect Triton to launch a sale of UK-headquartered specialty pharma asset Pharmanovia next year, according to three sources familiar with the situation.

Triton is expected to allocate a mandate in the first half of 2023, two of the sources said, with the other adding that it could come up for mandate as early as this year.

The sponsor is also closely monitoring the debt markets, waiting for liquid financing to re-open before starting a process, said one of the sources, adding that the exit is mostly likely to be a sale to another private equity fund.

Bringing in a minority investor and then looking to a public listing in 2024 could also be an option, said the same source. This strategy has been replicated at Cheplapharm, a German family-owned peer, which brought in EUR 550m growth capital from Atlantic Park and GIC with an IPO “remaining on the cards,” as reported.

The company recorded GBP 226m (EUR 260m) in sales in FY21, according to a Mansfield Advisors report. A deal could be value in the EUR 2.5bn – EUR 3bn range, one of the sources said.

Among deals in the space is EQT's take private of Swedish specialty pharma company Karo for 11.6x revenue in 2019, according to Mergermarket data. More recently EQT acquired the remaining 13.6% stake in Karo at a 7.08x revenue multiple, the same data reads.

Nordic Capital also this week exited specialty diagnostics company The Binding Site to US trade buyer Thermo Fisher for an 11.8x revenue multiple. 

Pharmanovia recorded EBITDA of EUR 112m in the year to 31 March 2021, nearly 3x growth on EUR 29m for nine months of 2020, according to its most recent filed accounts.

Its revenue in the same period was EUR 253m, up from EUR 111m, according to the same accounts.

The company was established as Atnahs Pharma which acquired the remaining stake it did not own in Pharmanovia in 2018. Triton then purchased a majority stake in the business in 2019.

Pharmanovia sells, markets and distributes branded prescription medicines globally. The company says it is a preferred acquirer for large-cap or specialty pharma companies choosing to divest established brands, according to its website.

It bought five drugs from AstraZeneca and a few from Roche – including Valium – in 2020. Four of these drugs contributed to the company’s top five drugs that generated 50% of revenue in 2021, according to the Mansfield Advisors’ report.

Cardiovascular remains the company’s largest segment, followed by endocrinology which houses Bonviva, the number one product by value in the portfolio, according to the report.

Neurology was the company’s largest segment before it acquired the cardiovascular drugs from AstraZeneca, the report reads. In September, Pharmanovia entered into an exclusive licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation in EMEA, a novel way to treat acute epilepsy seizures.

In July, it acquired commercial rights in China for Rocaltrol, an active form of vitamin D for treating osteoporosis, after owning global rights excluding China and Japan since 2020.

Triton and Pharmanovia declined to comment.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Healthcare
  • UK / Ireland
  • Triton Partners

More on Exits

Public sector software
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Lender taking the keys from a sponsor
Ares Management handed keys to two-thirds of UK sponsor’s portfolio

Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported

  • Financing
  • 30 August 2023
Luggage and airport services
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013